Argenica Therapeutics (AGN) Investor presentation summary

Investment highlights and clinical focus

• ARG-007 is a first-in-class neuroprotective drug with strong preclinical efficacy in reducing brain injury after stroke and other insults.

• Phase 2 trial data show a severity-dependent treatment effect, with more severe stroke patients benefiting most from ARG-007.

• Statistically significant improvements in functional outcomes were observed in patients with larger infarct cores, who typically have the worst post-stroke outcomes.

• The company is advancing to a targeted Phase 2b trial in moderate to severe stroke patients, guided by a world-leading clinical advisory committee.

• ARG-007 has shown significant efficacy in preclinical studies for traumatic brain injury and hypoxic ischaemic encephalopathy, broadening its potential applications.

Market opportunity and unmet need

• Stroke is the leading cause of long-term disability and death among neurological conditions, with US stroke-related costs reaching $56.5 billion in 2018–2019.

• Approximately 5 million people suffer acute ischaemic stroke globally each year, with 1.5 million experiencing large vessel occlusion strokes.

• Current treatments for severe stroke patients are inadequate, and ARG-007 is positioned to address this high-need segment.

• ARG-007 is safe and well tolerated in large vessel occlusion patients and demonstrates the greatest efficacy in those with larger infarct cores and slow collateral blood flow.

• The acute ischaemic stroke drug treatment market is projected to reach $10.6 billion by 2027.

Clinical trial results and next steps

• Phase 2 post hoc analysis revealed a significant treatment effect for ARG-007 in more severe stroke patients, confirmed by standardized imaging analysis.

• ARG-007 significantly reduced the growth of damaged brain tissue in moderate to severe stroke patients compared to placebo, especially in those with larger baseline infarct volumes.

• Statistically significant improvements in disability outcomes (mRS 0-3 at 90 days) were observed in patients with e-ASPECTS ≤6 treated with ARG-007.

• The upcoming Phase 2b trial will focus on moderate to severe stroke patients (ASPECTS 3-8), using AI-assisted imaging and validated endpoints, with a randomized, placebo-controlled, dose-response design.

• Key 2026 catalysts include regulatory milestones, clinical trial site selection, and large-scale manufacturing for stroke and TBI trials.